• argenx will acquire remaining shares in Unnatural Products in a deal valuing the company at up to approximately $1.15 billion.
• Terms include $550 million upfront from cash on hand, with up to $595 million contingent on development and regulatory milestones.
• The acquisition adds macrocyclic peptide discovery capabilities to support development of oral and long-acting treatments for serious immune-mediated diseases.
• Unnatural Products will retain its team and leadership in Santa Cruz, California, which will become the buyer’s peptide discovery hub.
• Closing is expected by the end of 2026, subject to customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090100PRIMZONEFULLFEED1001302467) on November 09, 2026, and is solely responsible for the information contained therein.